IRIS
GHIGLIOTTI, GIORGIO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 13.649
Totale 13.649
Salva come PNG Salva come JPEG
Nazione #
IT - Italia 13.649
Totale 13.649
Salva come PNG Salva come JPEG
Città #
Genova 10.648
Rapallo 1.864
Genoa 1.091
Bordighera 46
Totale 13.649
Salva come PNG Salva come JPEG
Nome #
Doxorubicin impairs the insulin-like growth factor-1 system and causes insulin-like growth factor-1 resistance in cardiomyocytes 160
Acute coronary syndromes do not promote prolonged in vivo FXII-dependent prothrombotic activity 157
Cell-cell bond modulates vascular smooth muscle cell responsiveness to Angiotensin II 155
Sublethal Doses of an Anti-erbB2 Antibody Leads to Death by Apoptosis in Cardiomyocytes Sensitized by Low Prosenescent Doses of Epirubicin: The Protective Role of Dexrazoxane. 148
Adipose tissue immune response: novel triggers and consequences for chronic inflammatory conditions. 146
Advanced Oxidation Protein Products-Modified Albumin Induces Differentiation of RAW264.7 Macrophages into Dendritic-Like Cells Which Is Modulated by Cell Surface Thiols. 144
Myostatin mediates abdominal aortic atherosclerosis progression by inducing vascular smooth muscle cell dysfunction and monocyte recruitment 134
C242T polymorphism in CYBA gene (p22phox) and risk of coronary artery disease in a population of Caucasian Italians 131
CD16+ monocyte subsets are increased in large abdominal aortic aneurysms and are differentially related with circulating and cell-associated biochemical and inflammatory biomarkers. 131
Resveratrol counteracts systemic and local inflammation involved in early abdominal aortic aneurysm development 131
N-acetyl-cysteine reduces neointimal thickening and procoagulant activity after balloon-induced injury in abdominal aortae of NewZealand white rabbits 130
Prevalent cardiac, renal and cardiorenal damage in patients with advanced abdominal aortic aneurysms 130
Thrombolysis in refractory unstable angina. 128
Doxorubicin induces senescence or apoptosis in rat neonatal cardiomyocytes by regulating the expression levels of the telomere binding factors 1 and 2 128
Carvedilol Prevents Doxorubicin-induced Free Radical release and Oxidative Damage in Cardiomyocytes. 125
Moderate increase of indoxyl sulfate promotes monocyte transition into profibrotic macrophages 125
Direct relationship between cell density and FDG uptake in asymptomatic aortic aneurysm close to surgical threshold: an in vivo and in vitro study. 123
Increased neutrophil lifespan in patients with congestive heart failure. 122
Aurintricarboxylic Acid attenuates intimal thickening after balloon injury of the rabbit aorta. 121
Doxorubicin-induced expression of LOX-1 in H9c2 cardiac muscle cells and its role in apoptosis 120
CYBA polymorphism associated with oxidative stress in Italian patients with early onset of coronary artery disease. 119
Serial Troponin for Early Detection of Nivolumab Cardiotoxicity in Advanced Non-Small Cell Lung Cancer Patients 118
Reduced coronary flow reserve in patients with primary hyperparathyroidism: a study by G-SPECT myocardial perfusion imaging. 117
Clinical stabilization of patients with unstable angina treated with thrombolytic therapy. 117
Carvedilol prevents doxorubicin-induced free radical release and apoptosis in cardiomyocytes in vitro. 116
Inhibition of Doxorubicin-Induced Senescence by PPARδ Activation Agonists in Cardiac Muscle Cells: Cooperation between PPARδ and Bcl6. 116
Short-term effect of rosuvastatin treatment on arterial stiffness in individuals with newly-diagnosed heterozygous familial hypercholesterolemia 116
Protective effects of Resveratrol in an experimental model of abdominal aortic aneurysm induction. 116
ALTERED CELL-FUNCTION ASSOCIATED TO LOSS OF CELL-MATRIX ADHESION: PRELIMINARY DATA ON A RAT AORTIC SMOOTH MUSCLE CELL LINE 115
Protective effects of carvedilol against doxorubicin-induced apoptosis in cardiac muscle cells 114
Maximal endothelial tissue plasminogen activator release is not impaired in patients with acute coronary syndromes before heparin treatment. 113
High doses of atorvastatin do not affect activity of prothrombinase in patients with acute coronary syndromes 111
Determinants of 6-month mortality in survivors of myocardial infarction after thrombolysis. Results of the GISSI-2 data base. The Ad hoc Working Group of the Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico (GISSI)-2 Data Base. 109
SOLUBLE FORM OF THE ENDOTHELIAL ADHESION MOLECULECD146 BINDS PREFERENTIALLY PROINFLAMMATORYPROATHEROSCLEROTICCD16+ MONOCYTE SUBSET 107
Prolonged activation of prothrombin on the vascular wall after arterial injury. 107
Metalloproteinases 2 and 9 are increased in plasma of patients with heart failure. 106
Causes and impact on survival of underuse of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in heart failure 106
Intravenous nifedipine prevents ergonovine-induced myocardial ischemia in patients with stable effort angina. 105
Pigmented nodular melanoma: The predictive value of dermoscopic features using multivariate analysis 103
Cyba polymorphism associated to oxidative stress in italian patients with early onset coronary artery disease. 4th meeting of the ETRO working party on population genetics of haemostatic risk factors for arterial vascular disease 101
Role of bone mineral density in the inverse relationship between body size and aortic calcification: Results from the Baltimore Longitudinal Study of Aging. 101
ERGONOVINE MALEATE TEST DETECTS ANGINAL PATIENTS WITH POORLY REPRODUCIBLE EXERCISE TESTS. 101
Indoxyl Sulfate Induces Renal Fibroblast Activation through a Targetable Heat Shock Protein 90-Dependent Pathway 100
Role of advanced oxidation protein products and Thiol ratio in patients with acute coronary syndromes 99
Carvedilol prevents mitochondrial membrane potential loss induced by doxorubicin in cardiomyocytes 98
Systemic levels of oxidative stress and title of autoantibodies in patients with ischemic heart disease at their first clinical manifestation. 98
Matrix metalloproteinase-2 and-9 are induced differently by doxorubicin in H9c2 cells: The role of MAP kinases and NAD(P)H oxidase 97
P38 MAPK and JNK antagonistically control senescence and cytoplasmic p16ink4a expression in doxorubicin-treated endothelial progenitor cells 96
Soluble form of the endothelial adhesion molecule CD146 binds preferentially CD16+ monocytes. 95
Myostatin: A Playmaker in Chronic Kidney Disease and Vascular Damage 95
Role of cell-cell bond for the viability and the function of vascular smooth muscle cells. 94
Plasmatic Levels of metalloproteinases 2 and 9 are increased in patients with congestive heart failure. 94
Postprandial serum induces apoptosis in endothelial cells: role of plymorphonuclear-derived myeloperoxidase and metalloproteinase-9 activity 92
Attivazione del fattore coagulativo XII in pz con angina stabile ed instabile 92
Intense lipid peroxidation in premature clinical coronary atherosclerosis is associated with metabolic abnormalities 91
Arterial hypertension in cancer: The elephant in the room 91
Gallopamil and diltiazem: a double-blind, randomized, cross-over trial in effort ischaemia. 90
Aspirin, but not heparin attenuates Xa/Va assembly after deep arterial injury of the rabbit aorta. 90
Early Age of onset of unstable angina is associated to major oxidative stress 90
N-acetyl-cysteine Regulates the Response to Injury in NZW Rabbit Aorta. 88
Ivabradine in Cancer Treatment-Related Left Ventricular Dysfunction 88
PROGENITOR CD34+ CELLS AND CIRCULATING ENDOTHELIAL CELLS IN PATIENTS WITH ACUTE OR CHRONIC HEART FAILURE 87
An increase in myocardial 18-fluorodeoxyglucose uptake is associated with left ventricular ejection fraction decline in Hodgkin lymphoma patients treated with anthracycline 87
Indoxyl sulfate: A candidate target for the prevention and treatment of cardiovascular disease in chronic kidney disease 87
Associazione tra lipoperossidazione ed insorgenza giovanile di aterosclerosi coronarica. 86
CD14CD16 monocyte subset levels in heart failure patients. 86
Plasma Levels of Matrix metalloproteinase-2 are increased in plasma of patients with heart failure. 85
Controllo antagonista di p38 e JNK nella regolazione della senescenza e di p16INK4A indotte dalla doxorubicina nei progenitori delle cellule endoteliali 85
Two Takayasu arteritis patients successfully treated with rituximab. 84
Plasma Levels of matrix metalloproteinase-9 and matrix metalloproteinase-2 are increased in plasma of patients with heart failure 84
Platelet-dependent and procoagulant mechanisms in arterial thrombosis. 83
Comparison between the potential protective mechanisms of carvedilol and atenolol against doxorubicin induced cardiac muscle cell damage and death in vitro. 82
LA DOXORUBICINA ALTERA L’ESPRESSIONE DELL’IGF-1R E DELL’IGFBP3 IN CELLULE MUSCOLARI CARDIACHE. UN NUOVO MECCANISMO DI CARDIOTOSSICITÀ 82
Systemic vascular inflammation in abdominal aortic aneurysm patients: a contrast-enhanced PET/CT study 81
Peaking time of CK-MB in patients treated with thrombolytic agents during myocardial infarction: is it really a clue to reperfusion? 81
PROGNOSTIC VALUE OF BIPHASIC RESPONSE DURING DOBUTAMINE STRESS ECHO AFTER MYOCARDIAL-INFARCTION 80
UN PASTO IPERLIPIDICO INDUCE STRESS OSSIDATIVO DERIVATODALL’ATTIVITÀ DELLA MIELOPEROSSIDASI E DETERMINA L’AUMENTO DELL’ATTIVITÀ DELLE METALLOPROTEASI 80
BASSE DOSI DI DOXORUBICINA PORTANO I CARDIOMIOCITI A MORTE TARDIVA PER CATASTROFE MITOTICA DOVUTA AD UNA ALTERATA REGOLAZIONE DELLE PROTEINE DEL TELOMERO: RUOLO DELLE MAPKs E DI p53 79
Elevated plasma levels of lipid peroxidation are associated to an early onset of UA 78
HETEROGENEITY AND DIFFERENT RELATIONSHIP WITH BIOCHEMICAL AND INFLAMMATORY BIOMARKERS FOR THE CIRCULATING CD16+ MONOCYTES SUBSETS IN ABDOMINAL AORTIC ANEURYSMS (AAA) 78
Repeated balloon injury of the rabbit aorta increases thrombin binding and platelet deposition. 78
Pruritus characteristics in a large Italian cohort of psoriatic patients 78
Decreased Neointimal Proliferation by Inhibition of von Willebrand Factor Function 77
Thrombolytic therapy in refractory unstable angina: the role of Holter monitoring. 76
Confronto fra meccanismi potenzialmente protettivi di carvedilolo e atenololo contro il danno e la morte di cellule muscolari cardiache indotti dalla doxorubicina in vitro. 76
Doxorubicin promotes metalloproteinases-2 trancriptional and zymographic activity in cardiac muscle cells via Nadph oxidase-derived reactive oxygen species. 76
Carbon nanotubes biocompatibility with Cardiac muscle cells 75
Doxorubicin impairs the insulin-like growth factor-1 axis in H9c2 cells 75
Familial Hypertophic Cardiomyopathy: many genes, how many diseases? 75
Reduction of cardiovascular morbidity and mortality in type 2 diabetes. A rational approach to hypoglycemic therapy 75
Hypercholesterolemia and coronary disease: Intervention strategies. [L'ipercolesterolemia e malattia coronarica: strategie di intervento.] 74
New therapeutic strategies in the management of congestive heart failure. 72
Autoanticorpi contro proteine ossidate in pazienti con recente sviluppo di angina instabile. 71
Identification of High-Risk Patients With Unstable Angina 69
La doxorubicina induce nei cardiomiociti la metalloproteasi di tipo 2 attraverso le specie reattive dell’ossigeno prodotte dalla NADPH ossidasi. 69
Prevalence and Undertreatment of Prothrombotic Risk in Advanced Forms of Liver Disease 69
Thrombus determinants of vascular cell activation. 69
Markers of oxidative stress evaluated in patients with ischemic heart disease at the time of their first clinical manifestation. 68
Time-course of acute myocardial infarction-dependent peripheral mobilisation of endothelial progenitor cells 68
Resveratrol modulates systemic and perivascular inflammation in experimental abdominal aortic aneurysm 68
Totale 9.934
Salva come PNG Salva come JPEG
Categoria #
all - tutte 35.118
article - articoli 30.047
book - libri 477
conference - conferenze 4.201
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 393
Totale 70.236
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/2019494 0 0 0 0 0 0 0 0 0 102 219 173
2019/20203.791 113 69 194 194 330 370 578 193 338 778 444 190
2020/2021786 51 79 43 80 23 69 20 71 108 94 71 77
2021/20222.033 26 183 176 264 91 95 102 508 50 183 75 280
2022/20232.232 229 121 15 244 416 377 22 187 359 15 210 37
2023/2024774 38 128 14 99 87 187 53 75 80 13 0 0
Totale 13.753